The device delivers real-time insights without needles, invasive sensors or cuffs. Global, multi-center trials conducted across the Mayo Clinic, AMCR Clinic – San Diego Cleveland Clinic – Abu Dhabi, and Hospital Sebarang Jaya – Penang, Malaysia, highlighted the technology’s capabilities for scalable, preventive care management.
San Jose, California-based LifePlus designed the wrist-worn device for real-time remote patient monitoring. Powered by AI, the technology delivers real-time insights into vital health parameters. It promotes proactive health management, early intervention and seamless information sharing.
More about the LifePlus data
LifePlus has collected and analyzed more than 70,000 paired multi-biomarker datapoints from more than 500 subjects across 14 countries throughout four different continents. The dataset spans skin tone, age, gender and BMI, according to LifePlus COO and Product GM Ben Mbouombouo.
Data shared at the American Diabetes Association’s 85th Scientific Sessions in Chicago highlighted the device’s performance against blood glucose monitoring (BGM). In head-to-head studies, it achieved a mean absolute relative difference (MARD, the standard of accuracy in glucose monitoring) of 10.8% against BGM references and 8.5% against the Dexcom G6 continuous glucose monitor (CGM) for a target dynamic range of 70-250 mg/dL.
LifeLeaf attained a low 2% outlier rate in blinded CGM studies. That proved comparable with invasive alternatives and underscores its clinical reliability, LifePlus says. Additionally, the device’s cuffless blood pressure feature demonstrated “impressive accuracy,” the company says.
Now, LifePlus plans to initiate additional longitudinal outcome studies for the device across Asia, Europe, the Middle East and North America.
“We’re incredibly encouraged by the clinical validation at world-class institutions like Mayo Clinic and Cleveland Clinic,” said Dr. Alodeep Sanyal, co-founder and CEO of LifePlus. “It confirms what we have believed from the beginning: that non-invasive, AI-powered monitoring can be reliable and scalable. The growing global interest from healthcare providers, partners and investors reaffirms that we are at the forefront of a major shift in how we manage and prevent chronic disease.”
